Jean Chalopin, the writer-producer who helped bring the Care Bears to television, now spends his days thinking about telomeres—the microscopic caps on our chromosomes that may be one of the keys to how long and how well we live.
It is an unlikely sentence, and Jean Chalopin knows it. At 76, the French-born storyteller behind some of the most beloved animation of the 1980s has turned his attention to the biology of human ageing, a subject he approaches with the same quality that once filled Saturday mornings with talking bears and a certain gadget-armed detective: an almost stubborn optimism that with persistence a hard problem can be solved.
“I’m an optimist by nature, this is true,” he says. “I always see the positive side of things.” That temperament built a cartoon studio that created titles that have stood the test of time, like Inspector Gadget, The Littles, or M.A.S.K. Now he is aiming it at one of the most universal problems there is, with hopes of helping people live long and live well.
How Jean Chalopin took Care Bears from greeting cards to a global brand
The Care Bears began not as a show but as artwork. The characters were painted by illustrator Elena Kucharik in 1981 for American Greetings, developed through the company’s Those Characters From Cleveland division. After two successful animated specials, American Greetings commissioned Chalopin’s studio, DIC, to produce a full television series, which premiered in September 1985 with Chalopin and Andy Heyward as executive producers.
Jean Chalopin is candid that Care Bears was a different kind of project from his original creations, contrasting it with a show like Inspector Gadget, which was built from scratch. The bears arrived with a point of entry already attached. What Chalopin and DIC brought was the craft of turning a static image into stories that resonated, and resonate still, with children who are now parents and grandparents themselves.
That endurance is something Chalopin finds genuinely moving.
“It’s great not to disappear,” he says of watching his old work continue to play. “Somehow the stories and character situations I was imagining continue to resonate in some way with multiple generations. It’s great, but the question is: why? Nobody really knows the reason why an audience continues to relate to a story or character over decades.”
The humility is real. So is the through-line that connects those bears to his work today: a belief that the right idea, cared for properly, outlives the moment that produced it.
Why longevity became the story
The move from entertainment to longevity science was not a mid-life swerve. Chalopin describes it as a natural extension of a lifelong pull toward the future, the same pull that produced the space-faring Ulysses 31 decades ago. What led to animated stories forty years ago leads him today toward the building of the future.
“Albert Einstein said that imagination is more important than knowledge. Today, I believe that imagination is the underlying force that makes us evolve and progress instead of stagnating,” he says. “More and more, I’m interested in how to build a future, and how to be part of the construction of the future, in spite of my age, using imagination as a raw ingredient, if I can hope to be part of that future myself.”
Ageing drew him because it touches everyone, and because he has watched what it does.
“A lot of people work very hard all their life, and their goal is to at some point retire and enjoy what’s ahead,” he says. “But then age comes, and you have pain, or deal with some debilitating disease, or any of the multiple issues linked to ageing, and instead of enjoying your retirement, you mostly deal with doctors and hospitals.”
His own stance is unsentimental. He has no plans to retire himself. “Being active is being alive. As much as I can, I want to continue having fun building something.” The point, for him, is not to stop, but to make sure that the people who do want to stop can enjoy it.
His distinction between lifespan and healthspan is the heart of the matter.
“If you’re in the hospital for the last ten years of your life, or home but unable to enjoy your surroundings and your family, what’s the point?” he asks. “But if you’re healthy, if you function well, if you walk and have good mobility, if you enjoy, if you can see your children and grandchildren and great-grandchildren, it’s a totally different thing.” Longevity, in his framing, is only worth pursuing if the years it adds are years worth living.
The science he keeps close
Chalopin speaks about cellular biology with fluency. He returns often to the Hayflick limit, the ceiling on how many times a normal human cell can divide before it stops dividing altogether. The concept was established by biologist Leonard Hayflick in 1961, who demonstrated that a healthy human cell population divides roughly 40 to 60 times before entering senescence, the state in which division ceases. Based on this limit, assuming that no other cause would lead to lifespan reduction, human cellular life could last about 120 years.
At the center of that limit sits the telomere, the protective cap on the end of each chromosome. As a cell divides, its telomeres shorten a little each time, until they can shorten no further. Chalopin folds this into a larger picture of the body under constant pressure, from pollutants, from radiation, and from the resulting oxidative stress that, given enough time, pushes cells toward death or toward becoming cancerous.
“We know that at some point we’re going to develop cancer if we live long enough,” he says, matter-of-factly, before pivoting straight back to what can be done about it.
He points to the outer edge of what is biologically possible. Jeanne Calment, the French woman who lived to 122, remains the oldest person whose age has been reliably documented, and Chalopin cites her as proof that the human ceiling is higher than most people assume. More and more people reach 100, then 104, then 106, he notes. The question that interests him is not whether such ages are possible, but how many people can reach them in good health.
“Ageing as a disease”: an optimist’s reframing
The phrase Chalopin uses most is one that can sound bleak until he explains it.
“Ageing treated as a disease,” he says. He means it as an invitation, not a diagnosis. If ageing is simply an inevitability, there is nothing to do but endure it. If it is treated as a problem with mechanisms, then those mechanisms can be studied, mapped, and, in time, addressed. “If we treat ageing as a disease, we can start to look at it differently.”
This is where his optimism does real work.
“If you’re a pessimist, you don’t build anything,” he says. “But if you’re an optimist, you believe you can. You believe you’re going to succeed. The power of conviction and belief is incredible. For that reason, I believe nearly everything is or will be possible, as long as you want it and you really do what you can for that.”
It is the same conviction he brings to storytelling and to business, applied to biology.
The practical expression of that conviction is a project he calls Bio Horizon, built around the idea of personal “health mapping.” No two people age the same way, he argues, because no two people carry the same mix of genetics, upbringing, environment, and exposure. We are “individuals” in all things.
“My health mapping is different than yours,” he says, “and it changes with external and internal factors, constantly.” The aim is to read those individual markers deeply, and monitor them regularly, drawing on genetic profiles and, where possible, on samples as easy to collect as saliva and urine, so that risks can be spotted, anticipated, and possibly treated “before this happens.” He is careful not to overpromise. “You cannot cover 100 percent of the cases,” he says, “but you can make people live way better by knowing their own health map and monitoring it.”
Building something that lasts
Chalopin insists the venture must stand on its own feet. When his wife asked whether he was pursuing it for profit or because he believed in it, he refused the premise that the two are opposed. “If it’s not able to generate profit, it will not survive,” he says. “You can have donations at the beginning, but hospitals, research centers, and clinical developments all need to be profitable. Otherwise you can’t attract talent, pay the doctors and nurses, or afford the equipment and facilities.” The goal is durability and the continuous support of progress, not wealth: “You need to think not of becoming rich, but of being profitable, because that’s the only way to keep your company going, growing, and succeeding.”
There is a neat symmetry in a career that begins with characters designed to last and arrives at a science aimed at helping people last. Chalopin does not force the comparison, but it is there in how he talks about both. The Care Bears endured because someone cared enough to make them well. Bio Horizon, in his telling, is the same instinct pointed at flesh and bone rather than ink and celluloid.
He frames the present moment as one of the most exciting of his life, precisely because the tools have finally caught up with the imagination. “We are on the front line of an explosion of learning and discovery, supported by an extraordinary convergence with what artificial intelligence can bring,” he says. He talks about coming breakthroughs against Alzheimer’s, Parkinson’s, cardiovascular diseases, and cancer with the passion and anticipation of someone reading the early pages of a story he cannot wait to finish. For a man who spent decades imagining the futures on TV screens, the appeal of longevity science is simple. This time, the future is real, and he intends to help build it.
